StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3048% below fair value
$143.82−4.00 (-2.71%)

Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –

Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of by Year

Alnylam Cumulative Total Shareholder Return (TSR) Value of Initial $100 Investment ($) ($)

Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of: $306 in FY2025, up 69.0% from a year earlier.

Latest, FY2025
306
Period ended Dec 31, 2025
Change on a year earlier
+69.0%
181 in FY2024
History
6 years
Since FY2020
Sources
2
Documents cited below

Where the FY2025 figure comes from

“|| 2025 | 14,867,600 | 77,428,521 | 6,582,418 | 19,817,949 | 305.96 | 124.75 | 313,747 | 2,986,549”

Source: Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of ($), annual FY2020–FY2025 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/proxy-tsr-100

See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?